Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Recombinant human insulin - Sanofi

Drug Profile

Recombinant human insulin - Sanofi

Alternative Names: HR 1799; Insulin HPR; Insulin Human Winthrop; Insuman; Insuman Comb 25; Insuman Implantable

Latest Information Update: 02 Jul 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Hoechst Marion Roussel Deutschland GmbH
  • Developer Sanofi
  • Class Antihyperglycaemics; Insulins; Pancreatic hormones
  • Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Type 1 diabetes mellitus; Type 2 diabetes mellitus

Most Recent Events

  • 02 Jul 2019 Recombinant human insulin is not yet available for type 1 diabetes in European Union (Intraperitoneal)
  • 01 Feb 2018 Sanofi completes a phase III trial for Type-1 diabetes mellitus in Belgium, France, Netherlands and Sweden (Intraperitoneal) (NCT01194882)
  • 23 Mar 2015 No recent reports on development identified - Phase-III for Type-2 diabetes mellitus in China (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top